EAM
CAI

Exome Asset Management’s Caris Life Sciences CAI Stock Holding History

Exome Asset Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Buy
+78,180
New +$1.4M 0.86% 42

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Exome Asset Management's CAI Position: Q2 2026 in Review

Exome Asset Management opened a new position in Caris Life Sciences (CAI) in Q2 2026: 78,180 shares worth $1.39M. The stake represents 0.86% of the portfolio and ranks #42 among its holdings.

246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Exome Asset Management held 78,180 shares of Caris Life Sciences worth $1.39M as of Q2 2026.
  • Caris Life Sciences was a new Exome Asset Management position in Q2 2026.
  • Caris Life Sciences made up 0.86% of Exome Asset Management's portfolio in Q2 2026, its #42 holding.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.